BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 38673842)

  • 1. Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics.
    Santoro N; Salutari P; Di Ianni M; Marra A
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.
    Miyamoto K; Minami Y
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia.
    Ma J; Ge Z
    Bosn J Basic Med Sci; 2021 Aug; 21(4):409-421. PubMed ID: 33577442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in acute myeloid leukemia.
    Newell LF; Cook RJ
    BMJ; 2021 Oct; 375():n2026. PubMed ID: 34615640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Changing Landscape of Treatment in Acute Myeloid Leukemia.
    Koenig K; Mims A; Levis MJ; Horowitz MM
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-12. PubMed ID: 32239961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.
    Kirtonia A; Pandya G; Sethi G; Pandey AK; Das BC; Garg M
    J Mol Med (Berl); 2020 Aug; 98(8):1069-1091. PubMed ID: 32620999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
    Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
    Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine.
    Casado P; Cutillas PR
    Mol Cell Proteomics; 2023 Apr; 22(4):100517. PubMed ID: 36805445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Changes During Acute Myeloid Leukemia (AML) Evolution and Identification of Novel Treatment Strategies Through Molecular Stratification.
    Karjalainen E; Repasky GA
    Prog Mol Biol Transl Sci; 2016; 144():383-436. PubMed ID: 27865463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy.
    Conneely SE; Stevens AM
    Curr Oncol Rep; 2021 Jan; 23(2):16. PubMed ID: 33439382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in Development.
    Konig H; Zeidner JF
    Curr Cancer Drug Targets; 2020; 20(7):471-472. PubMed ID: 32703130
    [No Abstract]   [Full Text] [Related]  

  • 13. Moving toward targeted therapies in acute myeloid leukemia.
    Gao W; Estey E
    Clin Adv Hematol Oncol; 2015 Nov; 13(11):748-54. PubMed ID: 27058701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A precision medicine approach to management of acute myeloid leukemia in older adults.
    Upadhyay Banskota S; Khanal N; Bhatt VR
    Curr Opin Oncol; 2020 Nov; 32(6):650-655. PubMed ID: 32826488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia.
    Tallman M
    J Natl Compr Canc Netw; 2018 May; 16(5S):656-659. PubMed ID: 29784749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
    Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
    J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards precision medicine for AML.
    Döhner H; Wei AH; Löwenberg B
    Nat Rev Clin Oncol; 2021 Sep; 18(9):577-590. PubMed ID: 34006997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A concise review on the molecular genetics of acute myeloid leukemia.
    Padmakumar D; Chandraprabha VR; Gopinath P; Vimala Devi ART; Anitha GRJ; Sreelatha MM; Padmakumar A; Sreedharan H
    Leuk Res; 2021 Dec; 111():106727. PubMed ID: 34700049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
    Venditti A; Piciocchi A; Candoni A; Melillo L; Calafiore V; Cairoli R; de Fabritiis P; Storti G; Salutari P; Lanza F; Martinelli G; Luppi M; Mazza P; Martelli MP; Cuneo A; Albano F; Fabbiano F; Tafuri A; Chierichini A; Tieghi A; Fracchiolla NS; Capelli D; Foà R; Alati C; La Sala E; Fazi P; Vignetti M; Maurillo L; Buccisano F; Del Principe MI; Irno-Consalvo M; Ottone T; Lavorgna S; Voso MT; Lo-Coco F; Arcese W; Amadori S
    Blood; 2019 Sep; 134(12):935-945. PubMed ID: 31395600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.